Figure 4.

Chimeric antigen receptor-modified T cells therapy targeting ovarian cancer. Leukapheresis harvests T lymphocytes from healthy persons. Viral vectors are used to modify genes using transgenic methods. Gene-directed knock-in technology involves recombining DNA and inserting it into CARs, suicide genes, or costimulatory receptors in lymphocytes.Next, anti-CD3/anti-CD28 beads and cytokines are employed to expand T cells. The αβ-TCR antibody magnetically eliminates any remaining αβ-TCR-positive cells. Finally, the harvested T cells will be administered into the patient’s body (130).